Baolan Li

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Baohui Han, Kai Li, Qiming Wang et al. · JAMA Oncology · 2018 · 620 citations · Full text

Medicine, Oncology, Pharmacology +17

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

Baohui Han, Kai Li, Yizhuo Zhao et al. · British Journal of Cancer · 2018 · 263 citations · Full text

Medicine, Oncology, Pharmacology +16

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study

Yunpeng Yang, Jiya Sun, Zhehai Wang et al. · Journal of Thoracic Oncology · 2021 · 148 citations · Full text

Medicine, Oncology, Pharmacology +17

Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial

Ying Cheng, Jianhua Chen, Wei Zhang et al. · Nature Medicine · 2024 · 121 citations · Full text

Medicine, Oncology, Pharmacology +16

Primary adenoid cystic carcinoma of the lung: Clinicopathological features, treatment and results

Mingming Hu, Ying Hu, Jiabei He et al. · Oncology Letters · 2015 · 66 citations · Full text

Medicine, Oncology, Molecular Oncology +14